Septerna, Inc. (SEPN)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
34.36 USD
-1.57
(-4.370%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 33.00 -1.36 (-1.364%) ⇩ (July 13, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:36 a.m. EDT
The investment case here is a classic high-risk biotech binary: massive potential upside if the hypoparathyroidism treatment succeeds, but zero downside protection given the lack of dividends and negative earnings. Fundamentally, the company shows explosive revenue growth (+120%) and a fortress balance sheet with negligible debt, yet it remains unprofitable with negative EPS, which caps the long-term rating at neutral despite the strong top-line momentum. The short-term outlook is bullish; the stock has rallied significantly off its lows, trading above key moving averages, and options flow confirms a heavy speculative bias toward a breakout. However, the statistical forecasting model offers virtually no guidance due to extreme noise, suggesting that while the narrative is positive, the immediate price path is volatile and driven entirely by event risk rather than predictable trends. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.174060 |
| MSTL | 0.202188 |
| MSTL_47 | 0.202525 |
| AutoARIMA | 0.202622 |
| AutoETS | 0.202625 |
| MSTL_30_47 | 0.203539 |
| MSTL_30 | 0.253975 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 54.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.088 |
| Excess Kurtosis | -1.39 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.101 |
| Revenue per Share | 1.625 |
| Market Cap | 1,548,795,264 |
| Forward P/E | -12.92 |
| Profit Margins | -49.88% |
| Website | https://septerna.com |
As of July 11, 2026, 2:36 a.m. EDT: Speculators are heavily skewed toward bullish exposure, with open interest concentrated in out-of-the-money calls (40 and 45 strikes for Jan '27) and significant volume in July and August calls. Put activity is minimal and focused on deep out-of-the-money strikes, indicating a lack of hedging against a crash and a speculative bet on a successful clinical trial or catalyst event driving a sharp rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9916737 |
| Address1 | 250 East Grand Avenue |
| All Time High | 38.04 |
| All Time Low | 4.17 |
| Ask | 34.44 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 818,210 |
| Average Daily Volume3 Month | 421,788 |
| Average Volume | 421,788 |
| Average Volume10Days | 818,210 |
| Bid | 25.2 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 8.426 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.36 |
| Current Ratio | 4.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 36.01 |
| Day Low | 33.9107 |
| Debt To Equity | 6.101 |
| Display Name | Septerna |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,392,000 |
| Earnings Timestamp Start | 1,786,392,000 |
| Ebitda | -66,559,000 |
| Ebitda Margins | -0.92117 |
| Enterprise To Ebitda | -18.397 |
| Enterprise To Revenue | 16.947 |
| Enterprise Value | 1,224,484,352 |
| Eps Current Year | -1.83899 |
| Eps Forward | -2.65924 |
| Eps Trailing Twelve Months | -0.8 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.6649 |
| Fifty Day Average Change | 3.6951008 |
| Fifty Day Average Change Percent | 0.12049936 |
| Fifty Two Week Change Percent | 199.16737 |
| Fifty Two Week High | 38.04 |
| Fifty Two Week High Change | -3.6800003 |
| Fifty Two Week High Change Percent | -0.096740276 |
| Fifty Two Week Low | 10.616 |
| Fifty Two Week Low Change | 23.744 |
| Fifty Two Week Low Change Percent | 2.2366238 |
| Fifty Two Week Range | 10.616 - 38.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,729,863,000,000 |
| Float Shares | 23,116,987 |
| Forward Eps | -2.65924 |
| Forward P E | -12.920985 |
| Free Cashflow | 24,014,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 130 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 72,255,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03175 |
| Held Percent Institutions | 1.02684 |
| Implied Shares Outstanding | 45,075,533 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-10-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California. |
| Long Name | Septerna, Inc. |
| Market | us_market |
| Market Cap | 1,548,795,264 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1765584396 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -36,040,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,619,563,900 |
| Number Of Analyst Opinions | 9 |
| Open | 35.64 |
| Operating Cashflow | 107,899,000 |
| Operating Margins | -0.50145 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 338 3533 |
| Post Market Change | -1.3642006 |
| Post Market Change Percent | -3.970316 |
| Post Market Price | 32.9958 |
| Post Market Time | 1,783,986,486 |
| Previous Close | 35.93 |
| Price Eps Current Year | -18.68417 |
| Price Hint | 2 |
| Price To Book | 4.0778546 |
| Price To Sales Trailing12 Months | 21.43513 |
| Profit Margins | -0.49879003 |
| Quick Ratio | 4.627 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -1.57 |
| Regular Market Change Percent | -4.36961 |
| Regular Market Day High | 36.01 |
| Regular Market Day Low | 33.9107 |
| Regular Market Day Range | 33.9107 - 36.01 |
| Regular Market Open | 35.64 |
| Regular Market Previous Close | 35.93 |
| Regular Market Price | 34.36 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 381,419 |
| Return On Assets | -0.08492 |
| Return On Equity | -0.09255999 |
| Revenue Growth | 120.11 |
| Revenue Per Share | 1.625 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 45,075,533 |
| Shares Percent Shares Out | 0.07 |
| Shares Short | 3,154,131 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,617,322 |
| Short Name | Septerna, Inc. |
| Short Percent Of Float | 0.1382 |
| Short Ratio | 6.72 |
| Source Interval | 15 |
| State | CA |
| Symbol | SEPN |
| Target High Price | 60.0 |
| Target Low Price | 38.0 |
| Target Mean Price | 45.0 |
| Target Median Price | 43.0 |
| Total Cash | 347,400,992 |
| Total Cash Per Share | 7.707 |
| Total Debt | 23,090,000 |
| Total Revenue | 72,255,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.21605 |
| Two Hundred Day Average Change | 8.143951 |
| Two Hundred Day Average Change Percent | 0.31064755 |
| Type Disp | Equity |
| Volume | 381,419 |
| Website | https://septerna.com |
| Zip | 94,080 |